Age range |
K. pneumoniae |
S. aureus |
E. coli |
Pseudomonas
|
CONS |
others |
Grand Total |
1 < |
1 |
1 |
|
2 |
3 |
|
7 |
2-21 |
13 |
16 |
9 |
8 |
10 |
|
56 |
22-41 |
42 |
24 |
17 |
14 |
17 |
2 |
116 |
42-61 |
38 |
17 |
22 |
19 |
7 |
3 |
106 |
62-81 |
36 |
10 |
15 |
13 |
9 |
7 |
91 |
82-101 |
2 |
3 |
1 |
|
1 |
|
7 |
|
132 |
71 |
64 |
57 |
47 |
12 |
383 |
Organism |
Departments |
|||||||
Surgery |
Orthopedics |
OBG |
ICU |
ENT |
GM |
NICU |
OTHERS |
|
Klebsiella pneumoniae |
92 |
6 |
8 |
8 |
5 |
4 |
1 |
8 |
S.aureus |
41 |
20 |
1 |
2 |
1 |
2 |
1 |
3 |
E. coli |
43 |
1 |
12 |
3 |
0 |
0 |
0 |
5 |
Pseudomonas aeruginosa |
40 |
5 |
1 |
0 |
4 |
1 |
2 |
3 |
CONS |
25 |
7 |
7 |
2 |
0 |
1 |
3 |
2 |
Others |
10 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Organisms |
Staphylococcus aureus ( n= 71) |
||||||
|
Sensitive |
Resistance |
|||||
Antibiotics |
Number |
Percentage |
Number |
Percentage |
|||
Amikacin |
64 |
90.1 % |
7 |
9.9 % |
|||
Amoxyclav |
33 |
46.5 % |
38 |
53.5 % |
|||
Azithromycin |
44 |
62 % |
27 |
38 % |
|||
Cefotaxime |
42 |
59.2 % |
29 |
40.8 % |
|||
Ceftriaxone |
43 |
60.6 % |
28 |
39.4 % |
|||
Linezolid |
70 |
98.5 % |
1 |
1.5
% |
|||
Ofloxacin |
38 |
53.5 % |
33 |
46.5 % |
|||
Pipercillin/ Tazobactam |
58 |
81.7 % |
13 |
18.3 % |
|||
Vancomycin |
68 |
95.8 % |
3 |
4.2 % |
|||
Cefoxitin |
45 |
63.4 % |
26 |
36.6 % |
Organism |
CONS (n=47) |
|||
|
Sensitive |
Resistance |
||
Antibiotics |
Number |
Percentage |
Number |
Percentage |
Amikacin |
35 |
74.5% |
12 |
25.5 % |
Amoxyclav |
26 |
55.3% |
21 |
44.7 % |
Cefotaxime |
25 |
53.2% |
22 |
46.8 % |
Ceftriaxone |
24 |
51.1% |
23 |
48.9 % |
Linezolid |
47 |
100% |
0 |
0 |
Ofloxacin |
25 |
53.2% |
22 |
46.8 % |
Pipercillin/ Tazobactam |
33 |
70.2% |
14 |
29.8 % |
Vancomycin |
46 |
97.7% |
1 |
2.3 % |
Organism |
Escherichia coli (n=64) |
|||
|
Sensitive |
Resistance |
||
Antibiotics |
Number |
Percentage |
Number |
Percentage |
Amikacin |
53 |
82.8 % |
11 |
17.2% |
Amoxyclav |
7 |
10.9 % |
57 |
89.1 % |
Cefotaxime |
13 |
20.3 % |
51 |
79.7 % |
Ceftriaxone |
7 |
10.9 % |
57 |
89.1 % |
Imipenum |
63 |
98.5 % |
1 |
1.5 % |
Ofloxacin |
31 |
48.4 % |
33 |
51.6 % |
Pipercillin/ Tazobactam |
49 |
76.6 % |
15 |
23.4 % |
Organism |
Klebsiella pneumoniae (n=132) |
|||
|
Sensitive |
Resistance |
||
Antibiotics |
Number |
Percentage |
Number |
Percentage |
Amikacin |
96 |
72.7 % |
36 |
27.3 % |
Amoxyclav |
12 |
9.1 % |
120 |
90.9 % |
Cefotaxime |
28 |
21.2 % |
104 |
78.8 % |
Ceftriaxone |
30 |
27.7 % |
102 |
72.3 % |
Imipenum |
124 |
93.9 % |
8 |
6.1 % |
Ofloxacin |
83 |
62.9 % |
49 |
37.1 % |
Pipercillin/ Tazobactam |
71 |
53.8 % |
61 |
46.2 % |
Organism |
Pseudomonas aeruginosa (n=56) |
|||
|
Sensitive |
Resistance |
||
Antibiotics |
Number |
Percentage |
Number |
Percentage |
Amikacin |
41 |
73.5 % |
15 |
26.8 % |
Amoxyclav |
19 |
33.9 % |
37 |
66.1 % |
Carbencillin |
40 |
71.4% |
16 |
28.6 % |
Cefotaxime |
21 |
37.5% |
35 |
62.5 % |
Ceftriaxone |
23 |
41.1 % |
33 |
58.9 % |
Gentamycin |
24 |
42.9 % |
32 |
57.1 % |
Imipenum |
52 |
92.9 % |
4 |
7.1 % |
Ofloxacin |
34 |
60.7 % |
22 |
39.3 % |
Pipercillin/ Tazobactam |
35 |
62.5 % |
21 |
37.5 % |